Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease


OBJECTIVES:To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).METHODS:Three groups of CD patients, in total 33 patients, treated with infliximab were… (More)
DOI: 10.1111/j.1572-0241.2007.01638.x

3 Figures and Tables


  • Presentations referencing similar topics